| 货号 | 11590-1mg |
| 描述 | Rapamycin (Item No. 13346) is an immunosuppressant that specifically interacts with the cytosolic FK-binding protein 12 to form a complex which inhibits the mammalian target of rapamycin (mTOR) pathway by directly binding to mTOR Complex 1. Temsirolimus is a dihydroxymethyl propionic acid ester of rapamycin with improved solubility that specifically inhibits mTOR signaling with a potency similar to that of rapamycin.1 Treatment with temsirolimus leads to cell cycle arrest in the G1 phase and also inhibition of tumor angiogenesis by reducing synthesis of VEGF.2,3 Temsirolimus demonstrates cytostatic activity in several xenograft models of human tumors in nude mice, including glioblastomas, prostate carcinoma, pancreatic, liver, and breast cancers, and medulloblastoma.2,4,3,1 |
| 别名 | CCI-779;Torisel®; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Dudkin, L.,Dilling, M.B.,Cheshire, P.J., et al. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clinical Cancer Research 7, 1758-1764 (2001). 2.Wan, X.,Shen, N.,Mendoza, A., et al. CCI-779 inhibits rhabdomyosarcoma xenograft growth by an antiangiogenic mechanism linked to the targeting of mTOR/Hif-1α/VEGF signaling. Neoplasia 8(5), 394-401 (2006). 3.Yu, K.,Toral-Barza, L.,Discafani, C., et al. mTOR, a novel target in breast cancer: The effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocrine-Related Cancer 8(3), 249-258 (2001). 4.Li, S.,Liang, Y.,Wu, M., et al. The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells. Cancer Cell Int. 13(1), (2013). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 1030.3 |
| 分子式 | C56H87NO16 |
| CAS号 | 162635-04-3 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |